From: TGen News
The FDA has approved a thyroid cancer drug successfully tested at Virginia G. Piper Cancer Center Clinical Trials, a partnership of Scottsdale Healthcare and Translational Genomics Research Institute. The FDA approved cabozantinib for the treatment of progressive, metastatic medullary thyroid cancer (MTC), a rare endocrine gland cancer affecting the thyroid. Previously, MTC patients had limited treatment options. The drug blocks the gene that causes a rare type of cancer, said Dr. Michael Demeure, the principal investigator on the Phase III clinical trial and endocrine surgeon at Scottsdale Healthcare.